Derek DiRocco, Ph.D.

Non-Executive Director

Derek DiRocco has been a member of the board of directors of Evommune since October 2024 and is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a member of the board of directors for 89Bio, Mineralys, Werewolf Therapeutics, Acrivon Therapeutics, Rivus Pharmaceuticals, Forward Therapeutics and Sera Medicines. Derek joined RA Capital in July 2013 and initially covered solid tumor oncology landscapes, later broadening coverage to multiple therapeutic areas. Derek holds a B.A. in Biology from Holy Cross College and a Ph.D. in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched signaling pathways responsible for chronic and acute kidney disease, as well as cellular mechanisms underlying fibrotic disease.